Researchers propose a non-invasive, accurate method for melanoma detection

NewsGuard 100/100 Score

A team of researchers from Kaunas University of Technology and Lithuanian University of Health Sciences proposed a non-invasive method for detection of melanoma. A patented computer-aided diagnostic system developed by Lithuanian scientists proved to be more than 90% accurate in detecting malignancy in diagnostic images of skin lesions acquired from 100 patients.

In Europe, melanoma is the fifth most common type of cancer and is the major cause of death from skin cancer. Northern Europe displays the largest age-standardized rate mortality of 3.8 per 10,000 in the region, with an incidence of 23.4.

Excision of a primary tumor remains essential in diagnosing melanoma, and the decision for the operation is generally based on the dermatoscopic evaluation of the lesion. However, the accuracy of melanoma clinical diagnosis is only at 65% and strongly relies on the experience of the physician-dermatologist carrying out the analysis.

The novelty of our method is that it combines diagnostic information obtained from different non-invasive imaging technologies such as optical spectrophotometry and ultrasound. Based on the results of our research, we can confirm that the developed automated system can complement the non-invasive diagnostic methods currently applied in the medical practice by efficiently differentiating melanoma from a melanocytic mole."

Renaldas Raisutis, Professor, Kaunas University of Technology

In the study, carried out by the researchers of two Lithuanian universities, diagnostic images of skin lesions acquired from 100 different patients were evaluated. By comparing and analyzing complex data on skin tumors recorded by different techniques, the researchers were able to develop a novel diagnostic system, differentiating melanoma from a benign nevus with accuracy higher than 90%.

"An efficient diagnosis of an early-stage malignant skin tumor could save critical time: more patients could be examined and more of them could be saved", says Prof Raisutis.

According to Prof Raisutis, the novel diagnostic system is firstly aimed at medical professionals; he estimates that the price of the final product might be affordable even for smaller medical institutions. However, the team is also thinking about the solutions for individual use at home.

Following the research, the prototype of the technology was developed, and the clinical research is being carried out complying with the requirements of the protocol for the clinical research confirmed by the regional bioethics committee.

The invention was patented in Lithuania (Patent No. LT6670B) and the patent applications filed for Patent Cooperation Treaty and the United States Patent and Trademark Office.

The above-described method and technology were developed within the framework of the project "SkinImageFusion: Complex Analysis Method of Spectrophotometric and Ultrasound Data for the Automatic Differential Diagnosis of Early Stage Malignant Skin Tumours", funded by Lithuanian Research Council and carried out by a joint team of Kaunas University of Technology and Lithuanian University of Health Sciences (the latter headed by Professor Skaidra Valiukeviciene) in 2017-2020. Three doctoral dissertations were defended on the basis of this research.

Source:
Journal reference:

Tiwari, K.A., et al. (2020) Diagnostics of Melanocytic Skin Tumours by a Combination of Ultrasonic, Dermatoscopic and Spectrophotometric Image Parameters. Diagnostics. doi.org/10.3390/diagnostics10090632.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First FDA-approved cellular therapy for metastatic melanoma available in South Florida